Company intelligence / Profile preview

Diamidex

Marseille, Provence-Alpes-Côte d'Azur, Francediamidex.com ↗

Ownership: Private
Employees: ~34
Development stage: Commercial

Overview

Diamidex has developed and commercialized rapid microbiological testing solutions that significantly reduce time-to-result for detecting key pathogens in water, pharmaceutical products, and industrial settings. The MICA platform enables detection of Legionella pneumophila in 48 hours versus the traditional 14 days, E. coli in as little as 6 hours versus one day, and similar improvements for other microorganisms[5]. The technology is validated by international installations and growing commercial adoption.

Modalities: DeviceReagent kitSoftware platform (AI-assisted image analysis)
Industry: Molecular Diagnostics

Partnerships

Distributors across EuropeMiddle EastChinaAfricaThailandNetherlandsCanada

Beyond the preview

Go deeper on Diamidex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamidex.

Explore the full profile